Amarantus Bioscience Holdings, Inc. is a biopharmaceutical holding company. The Company has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. It is developing ... More

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical holding company. The Company has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. It is developing diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company, through its subsidiary, Cutanogen Corporation, is developing a regenerative medicine cell therapy-based autologous skin replacement product, Engineered Skin substitute, which is in mid-stage clinical development, for the treatment of life-threatening severe burns. It is also developing a mid-stage clinical-stage pharmaceutical drug candidate, Eltoprazine, a small molecule 5HT1a/1b partial agonist for the treatment of symptomatic neurological disorders.